Stockscreener 앱 받기
1.20
4.00%
-0.05
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Peering Into Aquestive Therapeutics Inc's Recent Short Interest - Benzinga
Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2 - BioSpace
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity - Finviz
Sustained Therapeutics Reports Positive Phase 2 Results for Its Long-Acting Non-Opioid Medication for Chronic Pain - Yahoo Finance
Candid Therapeutics Plans to Initiate Multiple Phase 2 Studies Following Promising Clinical Data of T-cell Engagers in Autoimmune Diseases - Business Wire
Cognition Therapeutics Publishes Phase 2 Clinical Results - GlobeNewswire
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - Yahoo Finance
Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression - GlobeNewswire
Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Finviz
Beam Therapeutics Inc. (BEAM) reports updated data from BEACON Phase 1/2 Trial of Ristoglogene - MSN
Black Diamond Therapeutics’ Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data - Yahoo Finance
Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene - Finviz
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - PR Newswire
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Insider Monkey
Will Viridian Therapeutics Inc. stock outperform international peersJuly 2025 Update & Stepwise Trade Signal Implementation - Улправда
Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - Yahoo Finance
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewswire
Ratio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas - PR Newswire
Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results - GlobeNewswire
Sionna Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with - The Manila Times
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma - GlobeNewswire
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times
Kyverna Therapeutics to Report Topline Results from - GlobeNewswire
Contineum Therapeutics Submits Phase 2 Trial for PIPE-791 - The Globe and Mail
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street - Yahoo Finance
Rhythm Pharmaceuticals to Announce Preliminary Data from - GlobeNewswire
Phanes Therapeutics to Present Phase 1/2 Study Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026 - PR Newswire
Dyne Therapeutics Announces Positive Topline Results from - GlobeNewswire
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal - Seeking Alpha
Protara Therapeutics, Inc. (TARA) Discusses Updated Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC PatientsSlideshow (NASDAQ:TARA) 2025-12-04 - Seeking Alpha
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial - TradingView — Track All Markets
Protara Therapeutics, Inc. Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients - MarketScreener
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Relmada Therapeutics (RLMD) reports 9-month 92% CR for NDV-01 in NMIBC, eyes Phase 3 - Stock Titan
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Avalo Therapeutics, Inc. Updates Investor Presentation - TradingView
Black Diamond Therapeutics (Nasdaq: BDTX) to present silevertinib Phase 2 trial results in Dec. 3 webcast - Stock Titan
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - GlobeNewswire
Acumen Pharmaceuticals And 2 Other Penny Stocks Worth Watching - Yahoo Finance
Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Contineum Therapeutics, Inc. Reports Topline Data from its Phase 2 PIPE-307 Trial for the Treatment of Relapsing-Remitting Multiple SCLEROSIS - MarketScreener
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Business Wire
Protara (Nasdaq: TARA) Sees 100% Success in TARA-002 Pediatric LM Phase 2 Study - Stock Titan
Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women's Health - PR Newswire
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis - Business Wire
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease - GlobeNewswire
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis - Yahoo Finance
iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025 - PR Newswire
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting - Yahoo Finance
Intellia Therapeutics Presents Positive Pooled Phase 1/2 - GlobeNewswire
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - Intellia Therapeutics
Cadrenal Therapeutics, Inc. - TradingView
Xilio Therapeutics Announces Late-Breaking Phase 2 Data for - GlobeNewswire
Astria Therapeutics Announces Final Positive Results from All Enrolled HAE Patients in the ALPHA-STAR Phase 1b/2 Trial of Navenibart - Business Wire
4.73%
0.92%
자본화:
|
볼륨(24시간):